EUVIMEDEUVIMED entdecken
Open Access

Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants

Sumit Bansal, C Austin Zamarripa, Tory R Spindle, Elise M Weerts, Kenneth E Thummel, Ryan Vandrey, Mary F Paine iD, Jashvant D Unadkat iD

Clinical Pharmacology & Therapeutics · 2023-09 · 114 (3) · 693-703

DOI: 10.1002/cpt.2973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 30.06.2023. Verfasst von Sumit Bansal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Cannabinoids, Cannabis, Cannabidiol, Hallucinogens. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCCIH NIH HHS, National Center for Complementary and Integrative Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding cannabis‐drug interactions is critical given regulatory changes that have increased access to and use of cannabis. Cannabidiol (CBD) and Δ‐9‐tetrahydrocannabinol (Δ9‐THC), the most abundant phytocannabinoids, are in vitro reversible and time‐dependent (CBD only) inhibitors of several cytochrome P450 (CYP) enzymes. Cannabis extracts were used to evaluate quantitatively potential pharmacokinetic cannabinoid‐drug interactions in 18 healthy adults. Participant received, in a randomized cross‐over manner (separated by ≥ 1 week), a brownie containing (i) no cannabis extract (ethanol/placebo), (ii) CBD‐dominant cannabis extract (640 mg CBD + 20 mg Δ9‐THC), or (iii) Δ9‐THC‐dominant cannabis extract (20 mg Δ9‐THC and no CBD). After 30 minutes, participants consumed a cytochrome P450 (CYP) drug cocktail consisting of caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A). Plasma and urine samples were collected (0–24 hours). The CBD + Δ9‐THC brownie inhibited CYP2C19 > CYP2C9 > CYP3A > CYP1A2 (but not CYP2D6) activity, as evidenced by an increase in the geometric mean ratio of probe drug area under the plasma concentration‐time curve (AUC) relative to placebo (AUC GMR ) of omeprazole, losartan, midazolam, and caffeine by 207%, 77%, 56%, and 39%, respectively. In contrast, the Δ9‐THC brownie did not inhibit any of the CYPs. The CBD + Δ9‐THC brownie increased Δ9‐THC AUC GMR by 161%, consistent with CBD inhibiting CYP2C9‐mediated oral Δ9‐THC clearance. Except for caffeine, these interactions were well‐predicted by our physiologically‐based pharmacokinetic model (within 26% of observed interactions). Results can be used to help guide dose adjustment of drugs co‐consumed with cannabis products and the dose of CBD in cannabis products to reduce interaction risk with Δ9‐THC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsCannabisCannabidiolHallucinogensHumansAdultCytochrome P-450 CYP1A2Cytochrome P-450 CYP2C19CaffeineMidazolamCytochrome P-450 CYP3ALosartanCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P-450 CYP2D6Drug InteractionsOmeprazolePlant ExtractsDronabinol

Substanzen

CannabinoidsCytochrome P-450 CYP1A2Cytochrome P-450 CYP2C19CaffeineMidazolamCytochrome P-450 CYP3ALosartanCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemCytochrome P-450 CYP2D6

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
  • Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
  • Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington, USA.

ORCID-Profile: Mary F Paine, Jashvant D Unadkat

Förderung

  • NIDA NIH HHS
  • NCCIH NIH HHS
  • National Center for Complementary and Integrative Health
  • National Institute on Drug Abuse

Zitieren

APA

Bansal, S., Zamarripa, C. A., Spindle, T. R., Weerts, E. M., Thummel, K. E., Vandrey, R., Paine, M. F., & Unadkat, J. D. (2023). Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants. Clinical Pharmacology & Therapeutics, 114(3), 693-703. https://doi.org/10.1002/cpt.2973

Vancouver

Bansal S, Zamarripa CA, Spindle TR, Weerts EM, Thummel KE, Vandrey R, et al. Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants. Clinical Pharmacology & Therapeutics. 2023;114(3):693-703. doi:10.1002/cpt.2973

BibTeX
@article{Bansal2023,
  author = {Bansal, Sumit and Zamarripa, C Austin and Spindle, Tory R and Weerts, Elise M and Thummel, Kenneth E and Vandrey, Ryan and Paine, Mary F and Unadkat, Jashvant D},
  title = {Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {3},
  pages = {693--703},
  doi = {10.1002/cpt.2973}
}
Kostenlos starten →